Open AccessPembrolizumab (Keytruda)
Author(s) -
Reimbursement Team
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.186
Subject(s) - pembrolizumab , medicine , autologous stem cell transplantation , refractory (planetary science) , chemotherapy , oncology , immunotherapy , cancer , physics , astrobiology
CADTH recommends that Keytruda should be reimbursed by public drug plans for the treatment of adult and pediatric patients with refractory or relapsed classical Hodgkin lymphoma (cHL) if certain conditions are met.
Keytruda should only be reimbursed to treat patients who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT.
Keytruda should only be reimbursed as monotherapy and if the cost of pembrolizumab is reduced.